Given that our data and previous reports suggest STC2 is an estrogen-regulated protein [43], it is plausible that Dox disrupts the ER signaling pathways that typically drive STC2 overexpression in cancer cells, leading to the downregulation of estrogen-responsive genes, including STC2. The gene discussed is ESR1; the disease is cancer.